阿奇霉素治疗支原体肺炎对肝功能影响的相关因素及预后的临床研究

Clinical Research of Azithromycin in Treatment of Mycoplasma Pneumonia on Liver Function of the Related Factors and Prognosis

目的研究阿奇霉素治疗支原体肺炎肝功能损伤发生率及与患儿年龄、疗程的关系,肝功能恢复时间以及对治疗的影响,探讨阿奇霉素临床使用的安全性及对策。方法 2005年6月至2010年12月儿科病房收治的支原体肺炎患儿,阿奇霉素治疗前、第2疗程及第3疗程开始前分别抽取静脉血送检肝功能,异常者给予处理并复查。入院第8天X线胸片检查,异常者14d复查,并设100例同期住院的支原体肺炎患儿为对照组。结果肝功能损害发生率3.78%。与年龄密切相关,年龄越小,肝功能损害发生率越高,且随疗程延长而升高,肝功能恢复时间(9.41±2.39)d,总住院日及X线胸片恢复时间与肝功能正常组无差异。结论阿奇霉素治疗支原体肺炎是安全的,肝功能损害是可逆的。肝功能损害发生后,阿奇霉素减量或改为口服序贯治疗,并不影响疗效。

Objective Study the incidence of azithromycin treatment of mycoplasma pneumonia, liver function damage and children with age, the relationship of treatment, liver function recovery time and treatment, to explore the clinical use of azithromycin security and countermeasures. Methods June 2005 to mycoplasma pneumonia in children admitted to the pediatric ward in December 2010, before azithromycin treatment course of 2 and 3 of treatment before the start was extracted from venous submission liver function abnormalities were given to the processing and review. Admitted to hospital eight days X-ray chest X-ray examination, abnormalities in 14 days review of 100 cases of mycoplasma pneumonia in children hospitalized in the same period as the control group. Results Liver dysfunction incidence of 3.78%. Closely related to age, the younger, liver dysfunction, the higher the incidence of, and extend over a course of treatment increased, liver function recovery time of （9.41 ± 2.39） days, the total length of stay and the X-ray recovery time and normal liver function group differences, Conclusion Azithromycin treatment of myeoplasma pneumonia is safe, and liver function damage is reversible. The occurrence of liver dysfunction, azithromycin reduced or changed to oral sequential treatment does not affect the efficacy.